ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Which features best differentiate Sjögren's-related from non-Sjögren's-related dry eye disease?
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From immune activation to symptom burden: mechanisms and translational implications of immune-symptom uncoupling in Sjögren's disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify which features best differentiate Sjögren's-related from non-Sjögren's related dry eye disease (DED) using machine-learning models.
methodsA retrospective study was conducted on 324 individuals with DED based on Dry Eye Workshop-II criteria, including 162 with and 162 without Sjögren's disease (SjD). One eye per subject was randomly selected. Demographics, Ocular Surface Disease Index (OSDI), and clinical signs were collected. A symptom-sign discordance score was calculated (range - 1 to + 1), positive values indicated greater symptom burden relative to signs, and negative values indicated greater clinical signs relative to symptoms. Multiple machine learning models were developed, and the one with the highest accuracy was selected as optimal. Feature importance, Weight of Evidence (WoE), and Information Value (IV) were computed for the top five predictors in the optimal model.
resultsThe mean age was 47.4 years, and 82% of individuals were female. Compared to the non-SjD group, those with SjD had lower OSDI scores (31.8 vs. 44.6, p < 0.001) despite higher ocular surface staining (OSS) (Oxford IV 5.5% vs. 4.9, p = 0.015), shorter non-invasive tear break-up time (NIBUT) (8.6 vs. 10.6 s), lower Schirmer values (7.5 vs. 14.4 mm), and a higher rate of positive InflammaDry tests (73.4% vs. 25.3%, p < 0.001). Discordance scores for OSS (- 0.34 vs. +0.09, p < 0.001), NIBUT (- 0.60 vs. -0.39, p < 0.001), and Schirmer (- 0.46 vs. -0.39, p = 0.003) were more negative in the SjD compared to the non-SjD group, indicating that objective signs exceeded symptoms across all three metrics in the SjD group. The optimal model (accuracy = 0.96) identified the most predictive features of SjD-related DED as a positive InflammaDry test (WoE: 1.034, IV: 0.45), OSS discordance (score < - 0.5) (WoE: 1.376, IV: 0.42), NIBUT discordance (score < - 0.5) (WoE: 2.079, IV: 0.22), Schirmer test < 5 mm/5 min (WoE: 1.007, IV: 0.18), and Schirmer discordance (score < - 0.5) (WoE: 0.746, IV: 0.09).
conclusionSjD-related DED is characterized by ocular surface inflammation, symptom-sign discordance with signs outweighing symptoms, and a Schirmer test < 5 mm/5 min.
Identifiers
42417850What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.